AKAN
BEARISH
$0.82
Live
Akanda Corp. · NASDAQ
$0.81
52W Range
$46.45
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.73M
P/E
0.01
ROE
-60.9%
Profit margin
-266.3%
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.
Key Strengths
Graham Number suggests a defensive fair value of $281.01
Low Price/Book ratio (0.04) indicates potential undervaluation on asset basis
Debt/Equity ratio of 0.12 suggests conservative capital structure
Positive gross margin of 24.91% indicates some pricing power or cost control in production
Current ratio of 1.25 indicates short-term liquidity is adequate
Key Risks
Piotroski F-Score of 3/9 signals weak financial health and operational inefficiency
Negative profit, operating, and return metrics across the board (ROE: -60.86%, ROA: -28.69%)
No revenue or earnings growth data available, suggesting stagnation or collapse
Insider sentiment at 40/100 indicates cautious or neutral confidence
Technical trend at 0/100 confirms strong bearish momentum with no upward price signals
AI Fair Value Estimate
Based on comprehensive analysis
$281.01
+34127.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
70
10
15
10
0
AI Verdict
High Risk
Key drivers: Extremely low Piotroski F-Score, Negative profitability and growth, Lack of analyst coverage, Historical price collapse, No dividend or cash flow generation
Confidence
95%
Value
70/100
Ref P/E, PEG, Graham Number
Positives
- Graham Number of $281.01 provides a strong defensive floor
- Price/Book of 0.04 suggests deep undervaluation on book value
Watchpoints
- Current price of $0.82 is far below Graham Number, indicating market distrust
- No growth or earnings to support valuation
Future
10/100
Ref Growth rates
Positives
- No debt burden (Debt/Equity: 0.12) could support future restructuring
Watchpoints
- No available growth metrics (YoY/Q/Q revenue/earnings)
- Negative ROIC and no free cash flow data
- No analyst coverage or target prices
Past
15/100
Ref Historical trends
Positives
- Current ratio of 1.25 and quick ratio of 0.89 suggest liquidity stability
Watchpoints
- 5-year price change of -100% indicates complete capital destruction
- 1-year return of -96.4% and 6-month return of -95.4% show persistent decline
- No positive historical trends in performance
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low Debt/Equity ratio (0.12) indicates minimal leverage risk
Watchpoints
- Piotroski F-Score of 3/9 is critically low, signaling weak financial health
- No Altman Z-Score available, raising bankruptcy risk concerns
- Negative ROE, ROA, and profit margins indicate operational failure
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- Dividend strength is 0/100, indicating no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.82
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AKAN and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
Primary
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
|
LYRA
Lyra Therapeutics, Inc.
Peer
|
-99.9% | -99.5% | -87.8% | -91.8% | -50.8% | +32.6% |
|
INM
InMed Pharmaceuticals Inc.
Peer
|
-100.0% | -97.1% | -71.7% | -66.3% | -10.5% | +5.6% |
AKA
Akanda Corp.
Primary
5Y
-100.0%
3Y
-100.0%
1Y
-96.4%
6M
-95.4%
1M
-13.6%
1W
-6.7%
BDR
Biodexa Pharmaceuticals Plc
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-95.1%
6M
-75.6%
1M
-24.0%
1W
-4.0%
IMC
IM Cannabis Corp.
Peer
5Y
-99.9%
3Y
-91.4%
1Y
-72.7%
6M
-81.3%
1M
-57.0%
1W
+6.5%
LYR
Lyra Therapeutics, Inc.
Peer
5Y
-99.9%
3Y
-99.5%
1Y
-87.8%
6M
-91.8%
1M
-50.8%
1W
+32.6%
INM
InMed Pharmaceuticals Inc.
Peer
5Y
-100.0%
3Y
-97.1%
1Y
-71.7%
6M
-66.3%
1M
-10.5%
1W
+5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
0.01
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.04
P/S Ratio
2.06
EV/Revenue
-2.41
EV/EBITDA
0.55
Market Cap
$1.73M
Profitability
Profit margins and return metrics
Profit Margin
-266.31%
Operating Margin
-443.84%
Gross Margin
24.91%
ROE
-60.86%
ROA
-28.69%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
1.25
Good
Quick Ratio
0.89
Poor
Cash/Share
$17.33
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.85x
Healthcare Sector Comparison
Comparing AKAN against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
P/E Ratio
0.01
This Stock
vs
88.11
Sector Avg
-100.0%
(Discount)
Return on Equity (ROE)
-60.86%
This Stock
vs
-86.0%
Sector Avg
-29.2%
(Below Avg)
Profit Margin
-266.31%
This Stock
vs
-11.76%
Sector Avg
+2164.7%
(Superior)
Debt to Equity
0.12
This Stock
vs
3.51
Sector Avg
-96.6%
(Less Debt)
Current Ratio
1.25
This Stock
vs
3.67
Sector Avg
-65.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
|
LYRA
Lyra Therapeutics, Inc.
|
BEARISH | $1.15M | - | -6595.0% | -% | $0.65 | Compare |
|
INM
InMed Pharmaceuticals Inc.
|
BEARISH | $2.37M | - | -97.2% | -170.1% | $0.72 | Compare |
AKAN
Akanda Corp.
BEARISH
Mkt Cap
$2M
P/E
0.0
ROE
-60.9%
Price
$0.82
Past News Coverage
Recent headlines mentioning AKAN from our newsroom.
Newest → oldest
No matching news yet.